Price
$0.7931
Increased by +0.78%
Dollar Volume (20D)
328.4 K
ADR%
8.94
Earnings Report Date (estimate)
May 2, 24
Shares Float
36.68 M
Shares Outstanding
72.58 M
Shares Short
868.83 K
Market Cap.
59.55 M
Beta
2.34
Price / Earnings
N/A
20D Range
0.76 1.1
50D Range
0.62 1.2
200D Range
0.54 1.2
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Mar 12, 24 -0.22
Increased by +56.86%
-0.27
Increased by +18.52%
Nov 2, 23 -0.41
Increased by +6.82%
-0.47
Increased by +12.77%
Aug 3, 23 -0.43
Increased by +8.51%
-0.49
Increased by +12.24%
May 4, 23 -0.53
Increased by +36.9%
-0.48
Decreased by -10.42%
Mar 9, 23 -0.51
Increased by +42.7%
-0.47
Decreased by -8.51%
Nov 2, 22 -0.44
Increased by +43.59%
-0.58
Increased by +24.14%
Aug 4, 22 -0.47
Increased by +40.51%
-0.67
Increased by +29.85%
May 4, 22 -0.84
Decreased by -13.51%
-0.73
Decreased by -15.07%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 3.24 M
Decreased by -21.12%
-18.04 M
Increased by +3.11%
Decreased by -556.99%
Decreased by -22.82%
Jun 30, 23 6.89 M
Increased by +86.46%
-18.79 M
Increased by +5.69%
Decreased by -272.89%
Increased by +49.42%
Mar 31, 23 2.72 M
Increased by +5.91%
-22.95 M
Increased by +35.55%
Decreased by -843%
Increased by +39.14%
Dec 31, 22 3.54 M
Increased by +863.76%
-21.89 M
Increased by +41.97%
Decreased by -618.77%
Increased by +93.98%
Sep 30, 22 4.11 M
Increased by +167.14%
-18.62 M
Increased by +43.78%
Decreased by -453.51%
Increased by +78.96%
Jun 30, 22 3.69 M
Increased by +139.03%
-19.92 M
Increased by +33.18%
Decreased by -539.51%
Increased by +72.05%
Mar 31, 22 2.57 M
Increased by +182.53%
-35.62 M
Decreased by -28.69%
Decreased by -1.39 K%
Increased by +54.45%
Dec 31, 21 367 K
Increased by +103.48%
-37.71 M
Decreased by -9.57%
Decreased by -10.28 K%
Decreased by -3.25 K%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.